These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 35485446)

  • 1. Comparing Iridium-192 with Cobalt-60 sources in high-dose-rate brachytherapy boost for localized prostate cancer.
    Tamihardja J; Weick S; Lutyj P; Zimmermann M; Bratengeier K; Flentje M; Polat B
    Acta Oncol; 2022 Jun; 61(6):714-719. PubMed ID: 35485446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Two-Weekly High-Dose-Rate Brachytherapy Boost After External Beam Radiotherapy for Localized Prostate Cancer: Long-Term Outcome and Toxicity Analysis.
    Tamihardja J; Lutyj P; Kraft J; Lisowski D; Weick S; Flentje M; Polat B
    Front Oncol; 2021; 11():764536. PubMed ID: 34900712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Propensity score-matched analysis comparing dose-escalated intensity-modulated radiation therapy versus external beam radiation therapy plus high-dose-rate brachytherapy for localized prostate cancer.
    Tamihardja J; Lawrenz I; Lutyj P; Weick S; Guckenberger M; Polat B; Flentje M
    Strahlenther Onkol; 2022 Aug; 198(8):735-743. PubMed ID: 35551434
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.
    Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.
    Fang FM; Wang YM; Wang CJ; Huang HY; Chiang PH
    Jpn J Clin Oncol; 2008 Jul; 38(7):474-9. PubMed ID: 18621848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High-dose-rate brachytherapy boost for elderly patients with intermediate to high-risk prostate cancer: 5-year clinical outcome of the PROSTAGE cohort.
    Marotte D; Gal J; Schiappa R; Gautier M; Boulahssass R; Chand-Fouche ME; Hannoun-Levi JM
    Clin Transl Radiat Oncol; 2022 Jul; 35():104-109. PubMed ID: 35692263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes after Low-dose-rate versus High-dose-rate brachytherapy boost in combination with external beam radiation for intermediate and high risk prostate cancer.
    Dhere VR; Fischer-Valuck BW; Goyal S; Liu Y; Morgan TM; Ghavidel E; Moghanaki DM; Hershatter BW; Patel PR; Jani AB; Godette KD; Rossi PJ; Patel SA
    Brachytherapy; 2021; 20(6):1130-1138. PubMed ID: 34417136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with Hypofractionated External beam radiotherapy for localized prostate cancer: an analysis to determine the correlation between dose-volume histogram parameters in HDR brachytherapy and severity of toxicity.
    Ishiyama H; Kitano M; Satoh T; Kotani S; Uemae M; Matsumoto K; Okusa H; Tabata K; Baba S; Hayakawa K
    Int J Radiat Oncol Biol Phys; 2009 Sep; 75(1):23-8. PubMed ID: 19243900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High dose rate brachytherapy boost for prostate cancer: Biochemical control and the impact of transurethral resection of the prostate and hydrogel spacer insertion on toxicity outcomes.
    Chao M; Bolton D; Lim Joon D; Chan Y; Lawrentschuk N; Ho H; Spencer S; Wasiak J; Guerrieri M; Ow D; Troy A; Pham T; Sengupta S; Tan A; McMillan K; Koufogiannis G; Foroudi F; Ng M; Khoo V
    J Med Imaging Radiat Oncol; 2019 Jun; 63(3):415-421. PubMed ID: 30908894
    [TBL] [Abstract][Full Text] [Related]  

  • 12. External beam radiotherapy plus single-fraction high dose rate brachytherapy in the treatment of locally advanced prostate cancer.
    Boladeras A; Santorsa L; Gutierrez C; Martinez E; Pera J; Pino F; Suarez JF; Ferrer F; Díaz A; Polo A; Guedea F
    Radiother Oncol; 2014 Aug; 112(2):227-32. PubMed ID: 25174299
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined high dose rate brachytherapy and external beam radiotherapy for clinically localised prostate cancer.
    Strouthos I; Chatzikonstantinou G; Zamboglou N; Milickovic N; Papaioannou S; Bon D; Zamboglou C; Rödel C; Baltas D; Tselis N
    Radiother Oncol; 2018 Aug; 128(2):301-307. PubMed ID: 29764692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combined brachytherapy and ultra-hypofractionated radiotherapy for intermediate-risk prostate cancer: Comparison of toxicity outcomes using a high-dose-rate (HDR) versus low-dose-rate (LDR) brachytherapy boost.
    Kollmeier MA; Gorovets D; Flynn J; McBride S; Brennan V; Beaudry J; Cohen G; Damato A; Zhang Z; Zelefsky MJ
    Brachytherapy; 2022; 21(5):599-604. PubMed ID: 35725549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Late toxicity after single dose HDR prostate brachytherapy and EBRT for localized prostate cancer: Clinical and dosimetric predictors in a prospective cohort study.
    Büchser D; Casquero F; Espinosa JM; Perez F; Minguez P; Martinez-Indart L; Suarez F; Gonzalez A; Cacicedo J; San Miguel I; Maleta A; Gomez-Caamaño A; Bilbao P; Gomez-Iturriaga A
    Radiother Oncol; 2019 Jun; 135():13-18. PubMed ID: 31015158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life up to 10 years after external beam radiotherapy and/or brachytherapy for prostate cancer.
    Freiberger C; Berneking V; Vögeli TA; Kirschner-Hermanns R; Eble MJ; Pinkawa M
    Brachytherapy; 2018; 17(3):517-523. PubMed ID: 29496423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High-dose-rate brachytherapy monotherapy versus low-dose-rate brachytherapy with or without external beam radiotherapy for clinically localized prostate cancer.
    Yamazaki H; Masui K; Suzuki G; Nakamura S; Yamada K; Okihara K; Shiraishi T; Yoshida K; Kotsuma T; Tanaka E; Otani K; Yoshioka Y; Ogawa K
    Radiother Oncol; 2019 Mar; 132():162-170. PubMed ID: 30416045
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of patients with localized and locally advanced prostate cancer undergoing high-dose-rate brachytherapy with external-beam radiotherapy at our institute.
    Makino T; Mizokami A; Namiki M
    Anticancer Res; 2015 Mar; 35(3):1723-8. PubMed ID: 25750334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results of high dose rate afterloading brachytherapy boost to conventional external beam radiation therapy for initial and locally advanced prostate cancer.
    Pellizzon AC; Nadalin W; Salvajoli JV; Fogaroli RC; Novaes PE; Maia MA; Ferrigno R
    Radiother Oncol; 2003 Feb; 66(2):167-72. PubMed ID: 12648788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose-rate brachytherapy boost for locally advanced cervical cancer: Oncological outcome and toxicity analysis of 4 fractionation schemes.
    le Guyader M; Lam Cham Kee D; Thamphya B; Schiappa R; Gautier M; Chand-Fouche ME; Hannoun-Levi JM
    Clin Transl Radiat Oncol; 2022 Jan; 32():15-23. PubMed ID: 34816022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.